Brian Levy, MD
Internal Medicine · Edmond, OKNPI 1033186473
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,342 and has fallen 79.1% since, to $489 in 2025. Among internal medicine clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 100 payments — averaging $81.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$1K
- AbbVie$881
- GSK$825
- Amgen$679
- Amarin Pharma, Inc.$543
- plus $2K from 20 others
What the payments were for
- Speaking & faculty fees$1222%
- Food & beverage$8,01398%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 18 | $1,477 |
| AstraZeneca | 16 | $1,338 |
| AbbVie(2 entities) | 8 | $881 |
| GSK | 17 | $825 |
| Amgen | 6 | $679 |
| Amarin Pharma, Inc. | 5 | $543 |
| Esperion Therapeutics, Inc. | 2 | $250 |
| Regeneron Healthcare Solutions, Inc. | 2 | $191 |
| Pfizer | 4 | $183 |
| Johnson & Johnson | 5 | $161 |
| Novartis | 1 | $126 |
| Regeneron | 1 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Corcept Therapeutics | 1 | $124 |
| Eisai Inc. | 1 | $123 |
| Kowa Pharmaceuticals America, Inc. | 1 | $123 |
| Medicure Pharma Inc. | 1 | $122 |
| Acadia Pharmaceuticals Inc | 1 | $121 |
| Antares Pharma, Inc. | 1 | $118 |
| Astellas Pharma US Inc | 1 | $115 |
| Rhythm Pharmaceuticals, Inc. | 1 | $115 |
| Althera Pharmaceuticals LLC | 1 | $105 |
| Lilly USA, LLC | 2 | $91 |
| E.r. Squibb & Sons, L.L.C. | 1 | $54 |
| Medtronic | 1 | $16 |
| Corium, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,142 in reported general payments places this provider in the 90th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 34 | $50,679 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $50,195 |
| RybelsusSemaglutide | 17 | $29,218 |
| FarxigaDapagliflozin Propanediol | 25 | $26,587 |
| EliquisApixaban | 29 | $23,957 |
| JardianceEmpagliflozin | 22 | $13,064 |
| XareltoRivaroxaban | 14 | $10,243 |
| NamzaricMemantine Hcl/Donepezil Hcl | 13 | $10,031 |
| MyrbetriqMirabegron | 15 | $8,198 |
| Repatha SureclickEvolocumab | 12 | $6,408 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,604 |
| Rosuvastatin Calcium | 306 | $5,470 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $4,965 |
| Irbesartan | 116 | $2,940 |
| SynthroidLevothyroxine Sodium | 20 | $2,323 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,477 | $79,89651 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $825 | $55,79972 claims |
| AstraZenecaFarxiga | $1,338 | $26,58725 claims |
| PfizerEliquis, Paxlovid | $183 | $25,38670 claims |
| AbbVieNamzaric, Synthroid | $881 | $12,35433 claims |
| Johnson & JohnsonXarelto | $161 | $10,24314 claims |
| Astellas Pharma US IncMyrbetriq | $115 | $8,19815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Edmond
- Todd KrehbielEdmond$21K
- Ashlee WaughEdmond$15K
- William MorganEdmond$13K
- Thomas KupiecEdmond$12K
- Shawn SchlinkeEdmond$9K
- Emily ReedEdmond$8K
- Steve EgwuonwuLawton$464K
- Jesse RichardsTulsa$279K
- Ryan MorganOklahoma City$235K
- Madhuri LadTulsa$173K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.